← All stocks

Bausch Health Companies Inc.

BHC Net buying
CIK 0000885590 #1855 in the set updated 17 Sep 2026
Bought (120 mo)
$644.02M
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$393.43M
$810.34K on a plan · $6.85M straight out of an exercise
Sold at will
$385.77M
23 of 43 sales
Net
+$250.59M
+$258.25M against sales at will

By person

42 insiders · 97 transactions
13.1×

Thomas J. Appio holds 13.1 times base salary in stock. $16.28M of shares against $1.24M in salary for 2025.

Salary from the company's own proxy. The shares are what Thomas J. Appio last reported holding, valued at $7.03, the price Common Shares, No Par Value was last bought or sold at on the open market here, on 19 Aug 2026.

Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Paulson John
Director
$566.66M (22)
$113.78M (2)
+$452.88M
97,025,146
25.94%
$682.09M
+101.0%
Pershing Square Capital Management, L.P. entity
See footnote (3)
$250.89M (2)
−$250.89M
0
0.0000%
$0.00
−100.0%
ValueAct Holdings, L.P. entity
Director
$50.71M (3)
$18.25M (1)
+$32.47M
17,931,594
4.79%
$126.06M
+19.2%
PAULSON & CO. INC. entity
10% owner
$15.63M (1)
+$15.63M
73,255,869
19.59%
$514.99M
+3.5%
DE SCHUTTER RICHARD U
Director
$4.80M (12)
+$4.80M
387,207
0.1035%
$2.72M
+10,668%
ACKERMANN CHRISTINA
EVP AND GENERAL COUNSEL
$80.11K (1)
$4.53M (5) scheduled
−$4.45M
162,240
0.0434%
$1.14M
+172.3%
PAPA JOSEPH C
Director
$2.56M (4)
+$2.56M
1,427,568
0.3817%
$10.04M
+148.1%
Humphries William D.
President, Ortho-Dermatologics
$650.14K (1)
$3.08M (5) scheduled
−$2.43M
235,035
0.0628%
$1.65M
Miller Steven D
Director
$1.45M (2)
+$1.45M
239,224
0.0640%
$1.68M
+239,124%
Herendeen Paul
EVP and CFO
$724.85K (3)
+$724.85K
386,618
0.1034%
$2.72M
+157.7%
APPIO THOMAS
Chief Executive Officer
$584.02K (1)
+$584.02K
2,315,374
0.6191%
$16.28M
+10,765%
Eldessouky Sam
EVP & Chief Financial Officer
$538.59K (1)
−$538.59K
119,455
0.0319%
$839.77K
+122.1%
Gordon Joseph F
Pres&Co-Head Bausch&Lomb/Int'l
$494.47K (3)
−$494.47K
93,139
0.0249%
$654.77K
+130.6%
Carson Seana
EVP, General Counsel
$421.37K (14) scheduled
−$421.37K
616,761
0.1649%
$4.34M
+799.5%
WECHSLER AMY B
Director
$350.81K (1)
−$350.81K
314,979
0.0842%
$2.21M
+1,804%
Spurr Robert
President, U.S. Businesses
$348.16K (5)
−$348.16K
112,741
0.0301%
$792.57K
+180.1%
Lenar Aimee J.
President, US Pharma
$258.89K (1) scheduled
−$258.89K
334,853
0.0895%
$2.35M
Lee Frank D.
Director
$254.68K (2) scheduled
−$254.68K
95,210
0.0255%
$669.33K
McKenna Mark C.
President, Salix
$235.22K (1)
−$235.22K
20,756
0.0055%
$145.91K
−1.8%
Ross Thomas W. Sr.
Director
$112.49K (2)
+$112.49K
161,516
0.0432%
$1.14M
+654.1%
VON ESCHENBACH ANDREW C.
Director
$56.31K (2)
+$56.31K
38,647
0.0103%
$271.69K
+3,765%
Hale David Robert
Director
18,908,638
5.06%
$132.93M
+0.3%
Charhon Jean-Jacques
EVP, CFO
706,478
0.1889%
$4.97M
Kellen Ari
EVP, Company Group Chairman
630,842
0.1687%
$4.43M
−3.1%
Vadaketh Tom George
EVP, Chief Financial Officer
564,933
0.1511%
$3.97M
+455.9%
Rosiello Robert L.
EVP, Corp Dev & Strategy
517,683
0.1384%
$3.64M
−2.9%
POWER ROBERT N
Director
300,594
0.0804%
$2.11M
+827.2%
KAVANAGH SARAH B
Director
282,230
0.0755%
$1.98M
+1,908%
ROBERTSON RUSSEL C
Director
225,279
0.0602%
$1.58M
+1,322%
ICAHN BRETT
Director
220,280
0.0589%
$1.55M
Barresi John S
SVP, Controller & CAO
192,268
0.0514%
$1.35M
Whitaker Anne Clem
EVP, Company Group Chairman
158,885
0.0425%
$1.12M
−3.9%
Mulligan Richard
Director
155,616
0.0416%
$1.09M
+340.1%
Garcia Christian A
Director
135,578
0.0363%
$953.11K
KARABELAS ARGERIS N
Director
123,715
0.0331%
$869.72K
+508.8%
LEUNG SANDRA
Director
97,070
0.0260%
$682.40K
INGRAM ROBERT ALEXANDER
Director
92,046
0.0246%
$647.08K
+5.1%
GOETTLER MICHAEL
Director
76,020
0.0203%
$534.42K
LEE STEVEN HYOSIG
SVP, Controller & CAO
70,114
0.0187%
$492.90K
ROBERTS EIRY
Director
45,871
0.0123%
$322.47K
ESHELMAN FREDRIC N
Director
38,298
0.0102%
$269.23K
+115.2%
Munsch Frederick
SVP, Controller and CAO
22,435
0.0060%
$157.72K
+6.0%

Nothing of that kind in this period.

What was left out

Form 4 filings counted 539
Amendments (4/A) skipped 22
Filings about a different issuer 2
Unreadable filings 0
Joint filings 12
Sales on a Rule 10b5-1 plan 15
Sales straight out of an exercise 5
Sales at will 23
Transactions with no price 0
Shares from compensation/vesting 18,332,275
Sales filed before the plan box existed 22
History held since 4 Oct 2016